SG11202112980TA - Targeted protein degradation of parp14 for use in therapy - Google Patents
Targeted protein degradation of parp14 for use in therapyInfo
- Publication number
- SG11202112980TA SG11202112980TA SG11202112980TA SG11202112980TA SG11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA
- Authority
- SG
- Singapore
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 | |
| PCT/US2020/038377 WO2020257416A1 (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112980TA true SG11202112980TA (en) | 2021-12-30 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112980TA SG11202112980TA (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220388985A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986887A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022537349A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102993656B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114206853A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020296063B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025645A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142002A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA56513A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112980TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020257416A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3728207T (pt) | 2017-12-21 | 2023-03-14 | Ribon Therapeutics Inc | Quinazolinonas como inibidores de parp14 |
| WO2022150667A1 (en) * | 2021-01-08 | 2022-07-14 | The Board Of Regents Of The University Of Texas System | Nimbolide analogs and methods of use thereof |
| JP2024505228A (ja) * | 2021-01-29 | 2024-02-05 | ライボン・セラピューティクス・インコーポレイテッド | 炎症性疾患を処置する方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN117229224B (zh) * | 2022-06-07 | 2026-05-08 | 中国药科大学 | 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用 |
| CN119923391A (zh) * | 2022-07-29 | 2025-05-02 | 艾伯维新加坡运营私人有限公司 | 在疗法中使用的parp14的靶向蛋白降解 |
| CN119923394A (zh) * | 2022-07-29 | 2025-05-02 | 艾伯维新加坡运营私人有限公司 | 在疗法中使用的parp14的靶向蛋白降解 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (zh) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| SMT202000133T1 (it) * | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| EP4119552A1 (en) * | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| US20210154184A1 (en) * | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| PT3728207T (pt) | 2017-12-21 | 2023-03-14 | Ribon Therapeutics Inc | Quinazolinonas como inibidores de parp14 |
-
2020
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 KR KR1020217041538A patent/KR102993656B1/ko active Active
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/en not_active Ceased
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
- 2020-06-18 AU AU2020296063A patent/AU2020296063B2/en active Active
- 2020-06-18 CA CA3142002A patent/CA3142002A1/en active Pending
-
2025
- 2025-04-02 JP JP2025061199A patent/JP7844707B2/ja active Active
- 2025-05-22 US US19/216,120 patent/US20260125362A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114206853A (zh) | 2022-03-18 |
| JP2025102917A (ja) | 2025-07-08 |
| EP3986887A1 (en) | 2022-04-27 |
| WO2020257416A1 (en) | 2020-12-24 |
| BR112021025645A2 (pt) | 2022-02-01 |
| JP7844707B2 (ja) | 2026-04-13 |
| CN120398840A (zh) | 2025-08-01 |
| KR20220024098A (ko) | 2022-03-03 |
| CA3142002A1 (en) | 2020-12-24 |
| JP2022537349A (ja) | 2022-08-25 |
| AU2020296063A1 (en) | 2021-12-23 |
| AU2020296063B2 (en) | 2026-01-29 |
| MA56513A (fr) | 2022-04-27 |
| US20260125362A1 (en) | 2026-05-07 |
| KR102993656B1 (ko) | 2026-07-23 |
| US20220388985A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276464A (en) | Methods and preparations for administering therapeutic protein | |
| IL287082A (en) | Methods and preparations for targeted unloading of proteins | |
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| ZA201803661B (en) | Compositions and methods for decreasing tau expression | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| ZA201804223B (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| PT3990005T (pt) | Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria | |
| SI3532059T1 (sl) | Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| SG11201610947UA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| EP3886913A4 (en) | IMPROVED TARGETED DELIVERY OF THERAPEUTICS | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| IL318518A (en) | Targeted protein degradation of PARP14 for use in therapy | |
| HK40073749A (en) | Targeted protein degradation of parp14 for use in therapy | |
| IL318530A (en) | Targeted protein degradation of PARP14 for use in therapy | |
| GB201812861D0 (en) | Methods of administering therapy | |
| EP3579886A4 (en) | METHOD OF USE FOR THERAPEUTIC BONE ASSOCIATION | |
| HUE069517T2 (hu) | Eljárás fexapotid-triflutát terápiás hatékonyságának fokozására LUTS kezelésében | |
| HK40127147A (en) | Targeted protein degradation of parp14 for use in therapy | |
| HK40127146A (en) | Targeted protein degradation of parp14 for use in therapy | |
| AU2019903877A0 (en) | Inhibitors of protein kinases for use in therapy | |
| GB201913114D0 (en) | Targeted sequencing of y-chromosome |